期刊论文详细信息
Drugs in Context
Kawasaki disease in siblings and a review of drug treatment
article
Steven King-fan Loo1  Kam Lun Hon2  Alexander KC Leung3  Tak Cheung Yung4  Man Ching Yam5 
[1] The Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong;Department of Paediatrics & The Hong Kong Institute of Integrative Medicine, The Chinese University of Hong Kong;Department of Pediatrics, The University of Calgary and The Alberta Children’s Hospital;Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital;Department of Paediatrics, Prince of Wales Hospital
关键词: COVID-19;    dipyridamole;    intravenous immunoglobulin;    Kawasaki disease;   
DOI  :  10.7573/dic.2020-4-1
学科分类:社会科学、人文和艺术(综合)
来源: C S F Medical Communications Ltd.
PDF
【 摘 要 】

We have managed two anonymized siblings with Kawasaki disease (KD). The occurrence of KD in the elder brother alerted us to the occurrence of incomplete KD in the younger brother. Both siblings were treated with intravenous immunoglobulin and a high dose of dipyridamole with resolution of the coronary artery aneurysm. Dipyridamole was used instead of aspirin because both siblings were glucose-6-phosphate dehydrogenase deficient for which aspirin was contraindicated. To prevent damage to the coronary arteries, treatment should be started as soon as the diagnosis is made. There have been a lot of advances in medical therapy in recent years, which are reviewed together with conventional proven therapy for KD. Early diagnosis and prompt treatment are important to achieve optimal treatment outcome in KD. Family history of KD among siblings enables clinicians for an earlier diagnosis so as to prevent the disease complications particularly in patients with incomplete features.

【 授权许可】

CC BY-NC-ND   

【 预 览 】
附件列表
Files Size Format View
RO202307150001606ZK.pdf 246KB PDF download
  文献评价指标  
  下载次数:16次 浏览次数:0次